Key terms
About VINC
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VINC news
Apr 25
4:28pm ET
Vincerx Pharma offers to sell common stock, amount not stated
Apr 08
4:41pm ET
Vincerx: progress for VIP236 and VIP943 for solid tumors presented at AACR
Apr 03
2:01am ET
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)
Mar 06
11:18pm ET
Buy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug Pipeline
Mar 05
6:17pm ET
Vincerx Pharma to present three posters at AACR
No recent press releases are available for VINC
VINC Financials
Key terms
Ad Feedback
VINC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VINC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
